Metagenomi Therapeutics, Inc. MGX PHARMA
Company Overview
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.34.
Recent Developments
- Dec 2025 Revenue of $25.21M (-51.8% YoY); net profit $-87.87M.
- Trailing 12 Months Year-on-year growth — revenue -69.8%.
- 5-Year Trend Long-term compounding — revenue CAGR -24.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -24.95% |
| 1 Year: | -69.80% |
Stock Price Performance
| 1 Year: | -40.21% |
| 6 Months: | -27.50% |
| 3 Months: | -10.08% |
| 1 Month: | -5.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)38.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -24.9% CAGR over 5 years.
- Trading 65.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MGX Metagenomi Therapeutics, Inc. PHARMA | 1.16 | -0.47 | $43.82M | 0.00% | -48.45% | -60.61% | -24.95% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8.66M | 11.34M | 12.36M | 11.16M | 20.01M | 11.51M | 4.13M | 8.51M | 8.66M | 1.25M |
| Operating Income | -17.94M | -17.96M | -22.39M | -29.03M | -16.86M | -22.38M | -27.82M | -20.99M | -22.84M | -24.59M |
| Net Income | -16.13M | -13.01M | -19.82M | -25.15M | -10.74M | -18.77M | -25.04M | -19.91M | -20.39M | -23.06M |
| Diluted EPS | -4.74 | -3.82 | -5.82 | -1.19 | -0.29 | -0.51 | -0.68 | -0.54 | -0.55 | -0.61 |
| R&D Expense | 20.13M | 22.68M | 26.84M | 31.44M | 28.32M | 26.26M | 25.14M | 22.51M | 25.28M | 19.30M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 44.76M | 52.30M | 25.21M |
| Operating Income | -78.49M | -88.90M | -96.01M |
| Net Income | -68.25M | -78.06M | -87.87M |
| Diluted EPS | -20.05 | -2.36 | -2.36 |
| R&D Expense | 94.40M | 109.18M | 94.43M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | 364.84M | 324.60M | 221.10M |
| Total Equity | -74.43M | -135.58M | 234.86M | 158.60M |
| Cash & Equivalents | - | 140.60M | 27.39M | 41.72M |
| Total Liabilities | - | 149.67M | 89.74M | 62.51M |
| Current Liabilities | - | 68.86M | 37.31M | 22.93M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -91.41M | -109.07M | -88.89M |
| Investing Cash Flow | 45.73M | -88.16M | 103.53M |
| Financing Cash Flow | 1.01M | 84.01M | -356.00K |
| Capital Expenditure | -9.81M | -3.11M | -574.00K |
| Free Cash Flow | -101.22M | -112.19M | -89.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -175.4% | -170.0% | -380.9% |
| Net Margin % | -152.5% | -149.3% | -348.5% |
| ROE % | 50.3% | -33.2% | -55.4% |
| ROCE % | -26.5% | -30.9% | -48.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 2.85% | 1.08M | $1.19M |
| 2 | Renaissance Technologies, LLC | 1.97% | 742.40K | $816.64K |
| 3 | Catalio Capital Management, LP | 1.40% | 528.99K | $581.89K |
| 4 | Peapod Lane Capital LLC | 1.39% | 525.02K | $577.53K |
| 5 | Two Sigma Investments, LP | 1.36% | 513.70K | $565.07K |
| 6 | Bridgeway Capital Management, LLC | 1.06% | 400.30K | $440.33K |
| 7 | Wells Fargo & Company | 1.00% | 379.51K | $417.46K |
| 8 | Geode Capital Management, LLC | 0.76% | 288.67K | $317.53K |
| 9 | Pura Vida Investments, Llc | 0.70% | 264.39K | $290.83K |
| 10 | Blackrock Inc. | 0.68% | 257.63K | $283.39K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MGX
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPWmJ4WHhDQzJ6cldFTHZSQVY2SkVESm5fYzVMUWJYLW11LUV1OWdiaC11ZV85dEotNVYtQXN3Y1NMZHZPWFhmdEJKdW5QUmd4RlRwVWJ3M0EzYVU4S2hiRUYwSXBXWTcwWU4xMUxGSmJ6OVdqWmVYaXVSekRRZlZaMC1YYzg2aUdlM1lUaE…
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPdURqM2FlVUR0OE5hYmVBenRXN0FCRUVvdEYzM2RmcXBhX294SzF4N1prVmlxdWRJYTZfejNkYnZHZlZUT2Z1cU91ekhHMmlyb3pqRXdXdjV6X2FpN2tEVzFQWWR1TWhsZHIwYUs2QzlQRDVSWE9qRnJ3S1ZqOTlpSUVXRDIwbkVMa3Zwel…
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPdlVXbUpkZjdKN1dLbWdFU1BGY0xNN2gtTmtLQ3cxdVUxTmZtdnJOTFdKSnk0aDJJdFM5Rk9WQXV6UlpLRFVmX0FYZ05tMFg3N2o3aVdwUkU2RGhocExOS3pHUjBINkxUS1lseU1LOEpWVGFRNFFTTVMzVDRlbHNpSTN0aFRKemk1SG55Zl…
Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Price, MGX Stock News, MGX Share Price & Updates - kalkine.com.au
<a href="https://news.google.com/rss/articles/CBMiVEFVX3lxTE13N3RSYjA1RXNocmlHbUxQTmo0cURkX0lVdy04V25JOW05bV95c3NFa2dSSjJXZ0JqdlNuVmQ0OHpiVkRFZkREUTFaNmx3VHpfZ0tLWQ?oc=5" target="_blank">Metagenomi, Inc. Common Stock (NASDAQ: MGX) Share Pri…
Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX - tradingview.com
<a href="https://news.google.com/rss/articles/CBMidkFVX3lxTE9Rc0Rma2tvQzQ5SHM0MXo1TmNzRmM1bW5zLWZQRENDMzVVM2Z5ZTBNcC1UVjM5RnpONHgyNC1zN2RhN3dpU2ZKaXdHWkxqOFhMSzVHQU85WFM5VmtjQ2toUlJKQWZ6YXJIUmhTSWtaV1ZSM2hiYXc?oc=5" target="_blank">Metageno…
MGX Resources Posts Deeper Loss as Revenue Slumps but Expands Tanami Stake - The Globe and Mail
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxQTU94NjhJNVM3Y2lqUFltdHpFNUI3YWstbjBWTndoamxMREx6LXhueVhKSHZheXAzNDdtVkItWDNSMmxZa1pta3dYcVo4TjV6QzJ1RzZJSXJreFdueFBYTEk1VXNyOTdCRGdpMW81Z2ZKckt6UTFENkk2blNpRzFlbVhMXzJfU0lrZ0N2RG…
MGX — Frequently Asked Questions
What is the current share price of Metagenomi Therapeutics, Inc. (MGX)?
As of 2026-09-19 21:16 PDT, Metagenomi Therapeutics, Inc. (MGX) trades at $1.16 on NasdaqGS. Its 52-week range is $1.14 to $3.35.
What is the market capitalisation of MGX?
Metagenomi Therapeutics, Inc. (MGX) has a market capitalisation of $43.82M on NasdaqGS.
What is the P/E ratio of MGX?
MGX trades at a trailing price-to-earnings (P/E) ratio of -0.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.37.
What is the return on equity (ROE) of MGX?
MGX has a return on equity (ROE) of -60.61%. Its return on capital employed (ROCE) is -48.45%.
Is MGX a good stock to buy?
This page provides a data-driven analysis of Metagenomi Therapeutics, Inc. (MGX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.